You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

CLINICAL TRIALS PROFILE FOR REGORAFENIB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Regorafenib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01002378 ↗ The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib Completed Bayer Phase 1 2009-10-01 An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed Bayer Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed Brigham and Women's Hospital Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed Fox Chase Cancer Center Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Regorafenib

Condition Name

Condition Name for Regorafenib
Intervention Trials
Colorectal Cancer 26
Metastatic Colorectal Cancer 25
Colorectal Neoplasms 22
Hepatocellular Carcinoma 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Regorafenib
Intervention Trials
Colorectal Neoplasms 104
Carcinoma 36
Carcinoma, Hepatocellular 31
Gastrointestinal Stromal Tumors 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Regorafenib

Trials by Country

Trials by Country for Regorafenib
Location Trials
United States 626
Italy 108
China 87
Japan 87
Germany 75
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Regorafenib
Location Trials
California 45
Florida 34
Texas 31
New York 30
Pennsylvania 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Regorafenib

Clinical Trial Phase

Clinical Trial Phase for Regorafenib
Clinical Trial Phase Trials
Phase 4 5
Phase 3 26
Phase 2/Phase 3 4
[disabled in preview] 133
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Regorafenib
Clinical Trial Phase Trials
Recruiting 82
Completed 63
Not yet recruiting 35
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Regorafenib

Sponsor Name

Sponsor Name for Regorafenib
Sponsor Trials
Bayer 85
National Cancer Institute (NCI) 15
Asan Medical Center 10
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Regorafenib
Sponsor Trials
Other 261
Industry 171
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.